Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Splicing variants in MYRF cause partial loss of function in the retinal pigment epithelium leading to nanophthalmos
Gabrielle M. Rozumek, Michelle L. Brinkmeier, Bin Guan, Su Qing Wang, Catherine Tower, Nina T. Yang, Rachel S. Lim, Dejuan Kong, Daniel Soden, Qitao Zhang, John Y.S. Han, Jason M.L. Miller, Lijin Dong, D. Ford Hannum, Sayoko E. Moroi, Julia E. Richards, Robert B. Hufnagel, Lev Prasov
Gabrielle M. Rozumek, Michelle L. Brinkmeier, Bin Guan, Su Qing Wang, Catherine Tower, Nina T. Yang, Rachel S. Lim, Dejuan Kong, Daniel Soden, Qitao Zhang, John Y.S. Han, Jason M.L. Miller, Lijin Dong, D. Ford Hannum, Sayoko E. Moroi, Julia E. Richards, Robert B. Hufnagel, Lev Prasov
View: Text | PDF
Research Article Genetics Ophthalmology

Splicing variants in MYRF cause partial loss of function in the retinal pigment epithelium leading to nanophthalmos

  • Text
  • PDF
Abstract

Improper light focus on the retina, refractive error, is primarily caused by eye size differences and is the leading cause of vision loss worldwide. C-terminal variants in the Myelin regulatory factor (MYRF) gene, a retinal pigment epithelium–derived (RPE-derived) transcription factor, lead to isolated nanophthalmos characterized by a small, though structurally sound eye. However, other MYRF loss-of-function variants cause syndromic disease. To address this discrepancy, in vitro and animal studies were performed on a pathogenic C-terminal variant dG-MYRF (p.Gly1126fs30*, c.3376-1G>A). Human RPE cells or primary RPE transduced with dG-MYRF showed reduced target gene expression, with decreased steady-state levels of the C-terminal cleavage product, but normal cleavage and localization. A homozygous humanized MYRF C-terminal mouse model (MyrfhumdG/humdG) was embryonic lethal by E18.5, while WT (MyrfhumWT/humWT) mice were viable. Single-cell RNA-seq from E17.5 MyrfhumdG/humdG and KO RxCre;Myrffl/fl (E15.5 and P0) mice revealed shared differentially expressed genes, with decreased effect size in the MyrfhumdG/humdG eyes. These findings support dG-MYRF as a hypomorphic allele. Additionally, 2 MYRF splicing variants creating nonfunctional isoforms were found in families with isolated nanophthalmos. Overall, hypomorphic MYRF alleles underlie isolated nanophthalmos, supporting a tissue-specific threshold effect and highlighting unique roles for the MYRF C-terminus in the RPE.

Authors

Gabrielle M. Rozumek, Michelle L. Brinkmeier, Bin Guan, Su Qing Wang, Catherine Tower, Nina T. Yang, Rachel S. Lim, Dejuan Kong, Daniel Soden, Qitao Zhang, John Y.S. Han, Jason M.L. Miller, Lijin Dong, D. Ford Hannum, Sayoko E. Moroi, Julia E. Richards, Robert B. Hufnagel, Lev Prasov

×

Figure 7

Deep intronic variants in MYRF alter splicing of mRNA transcript.

Options: View larger image (or click on image) Download as PowerPoint
Deep intronic variants in MYRF alter splicing of mRNA transcript.
(A and...
(A and B) Two families were discovered with intronic variants in MYRF. (C) Schematic of the minigene RNA splicing assay and predicted products. Minigene for variant c.460+167G>A (A) show altered splicing of MYRF at the mRNA level for 39% of transcripts from sample from Family 1, suggesting a ~19% usage overall (n = 18 colonies). (D) cDNA and predicted splicing of c.3194+122A>G (B) variant amplified from MYRF RNA in patient blood from Family 2. PCR amplification of cDNA shows altered splicing at the mRNA level for 15% of transcripts (30% for the allele) (n = 20 colonies).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts